GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppressionDilan Athauda, Sonia Gandhi, Patricia Lopez-Garcia et al.|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 7
TDP-43 loss of function drives aberrant splicing in Parkinson’s diseaseJonathan Brenton, Mina Ryten, Jordan Follett et al.|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 1